Treatment Results of CyberKnife Radiosurgery for Patients with Primary or Recurrent Non-Small Cell Lung Cancer

Kim, Woo Chul; Kim, Hun Jung; Park, Jeong Hoon; Huh, Hyun Do; Choi, Sang Huoun

doi:10.3857/jkstro.2011.29.1.28

Cited by 4 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous studies, CKRS also showed good outcomes, with a local control rate at 2 years of 86%-100% in patients with inoperable early stage NSCLC with minor complications, such as grade 1-2 radiation pneumonitis, mild chest wall discomfort [ 17 18 19 20 21 ] ( Table 6 ). The advantages of CKRS are the ability to perform real-time tumor tracking, which makes it possible to reduce the target volume by eliminating the margin of the internal target volume.…”

Section: Discussionmentioning

confidence: 80%

Clinical outcome of fiducial-less CyberKnife radiosurgery for stage I non-small cell lung cancer

et al. 2015

View full text Add to dashboard Cite

PurposeTo evaluate the treatment results in early stage non-small cell lung cancer patients who have undergone fiducial-less CyberKnife radiosurgery (CKRS).Materials and MethodsFrom June 2011 to November 2013, 58 patients underwent CKRS at Asan Medical Center for stage I lung cancer. After excluding 14 patients, we retrospectively reviewed the records of the remaining 44 patients. All analyses were performed using SPSS ver. 21.ResultsThe median age at diagnosis was 75 years. Most patients had inoperable primary lung cancer with a poor pulmonary function test with comorbidity or old age. The clinical stage was IA in 30 patients (68.2%), IB in 14 (31.8%). The mean tumor size was 2.6 cm (range, 1.2 to 4.8 cm), and the tumor was smaller than 2 cm in 12 patients (27.3%). The radiation dose given was 48-60 Gy in 3-4 fractions. In a median follow-up of 23.1 months, local recurrence occurred in three patients (2-year local recurrence-free survival rate, 90.4%) and distant metastasis occurred in 13 patients. All patients tolerated the radiosurgery well, only two patients developing grade 3 dyspnea. The most common complications were radiation-induced fibrosis and pneumonitis. Eight patients died due to cancer progression.ConclusionThe results showed that fiducial-less CKRS shows comparable local tumor control and survival rates to those of LINAC-based SABR or CKRS with a fiducial marker. Thus, fiducial-less CKRS using Xsight lung tracking system can be effectively and safely performed for patients with medically inoperable stage I non-small cell lung cancer without any risk of procedure-related complication.

show abstract

Section: Discussionmentioning

confidence: 80%

Clinical outcome of fiducial-less CyberKnife radiosurgery for stage I non-small cell lung cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…For the control of NSCLC, it has been suggested that an overall treatment period shorter than kick-off time (Tk) (less than 4 weeks) has advantages over simple dose escalation with conventional fractions [10]. SABR with a large fraction size can achieve favorable local control for early stage NSCLC, which makes it the current standard treatment for medically inoperable patients [1,6-8]. …”

Section: Discussionmentioning

confidence: 99%

“…Three-dimensional conformal radiation therapy (3D-CRT) allows the formulation of a complex multiple-field plan, and makes it possible to protect normal tissue from high doses of radiotherapy, while maintaining target coverage. The recently introduced stereotactic ablative radiotherapy (SABR) regimen yields high local control rates (85-95%) and acceptable toxicities in early stage NSCLC [6-8]. …”

Section: Introductionmentioning

confidence: 99%

Hypofractionated three-dimensional conformal radiotherapy for medically inoperable early stage non-small-cell lung cancer

Lee

Kim

et al. 2013

Radiat Oncol J

View full text Add to dashboard Cite

PurposeThe purpose of this study was to assess the clinical outcomes of hypofractionated radiotherapy (HFRT) with three-dimensional conformal technique for medically inoperable patients with early stage non-small-cell lung cancer (NSCLC) and to evaluate prognostic factors.Materials and MethodsWe performed a retrospective review of 26 patients who underwent HFRT for early stage NSCLC between September 2005 and August 2011. Only clinical stage T1-3N0 was included. The median RT dose was 70 Gy (range, 60 to 72 Gy) and the median biologically equivalent dose (BED) was 94.5 Gy (range, 78.0 to 100.8 Gy). In 84.6% of patients, 4 Gy per fraction was used. Neoadjuvant chemotherapy with paclitaxel and cisplatin was given to 2 of 26 patients.ResultsThe median follow-up time for surviving patients was 21 months (range, 13 to 49 months). The overall response rate was 53.9%, and the initial local control rate was 100%. The median survival duration was 27.8 months. Rates of 2-year overall survival, progression-free survival (PFS), local control (LC), and locoregional-free survival (LRFS) were 54.3%, 61.1%, 74.6%, and 61.9%, respectively. Multivariate analysis showed that BED (>90 vs. ≤90 Gy) was an independent prognostic factor influencing PFS, LC, and LRFS. Severe toxicities over grade 3 were not observed.ConclusionRadical HFRT can yield satisfactory disease control with acceptable rates of toxicities in medically inoperable patients with early stage NSCLC. HFRT is a viable alternative for clinics and patients ineligible for stereotactic ablative radiotherapy. BED over 90 Gy and 4 Gy per fraction might be appropriate for HFRT.

show abstract

Oncologic Outcomes of Surgery Versus SBRT for Non–Small-Cell Lung Carcinoma: A Systematic Review and Meta-analysis

Ijsseldijk

Shoni

Siegert

et al. 2021

Clinical Lung Cancer

View full text Add to dashboard Cite

Treatment Results of CyberKnife Radiosurgery for Patients with Primary or Recurrent Non-Small Cell Lung Cancer

Cited by 4 publications

References 25 publications

Clinical outcome of fiducial-less CyberKnife radiosurgery for stage I non-small cell lung cancer

Clinical outcome of fiducial-less CyberKnife radiosurgery for stage I non-small cell lung cancer

Hypofractionated three-dimensional conformal radiotherapy for medically inoperable early stage non-small-cell lung cancer

Oncologic Outcomes of Surgery Versus SBRT for Non–Small-Cell Lung Carcinoma: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About